This is a Phase I/II trial of the use of a monoclonal F(ab')2 fragment conjugated to the A chain of ricin. The monoclonal antibody recognizes the CD5 cell surface protein. T cells that are CD5+ internalize the immunotoxin and are killed, thus reducing the number of infused T cells and reducing the risk of GvHD. We are assessing the therapy for rate of engraftment and rate of development of graft vs. host disease.
Showing the most recent 10 out of 721 publications